Search clinical trials for: mirabegron OCAS

Total 391 results

Astellas Pharma Inc

Completed

A Study to Find Out How Much Mirabegron Gets Into the Body After Dosing With a Tablet Formulation

Healthy Subjects | Bioavailability | Pharmacokinetics of Mirabegron

Netherlands
Astellas Pharma Inc

Completed

To Evaluate the Blood and Urine Concentration and the Safety and Tolerability of Increasing Repeated Doses of Mirabegron (YM178) OCAS in Healthy Young and Elderly Males and Healthy Young and Elderly Females

Healthy Subjects | Pharmacokinetics

Netherlands
Astellas Pharma Europe B.V.

Completed

A Study to Compare the Actions in the Body of Healthy Subjects of Three Modified Release Formulations of YM178 Under Fasted and Fed Conditions With One Immediate Release Formulation of YM178 Under Fasted Conditions

Healthy Subjects | Pharmacokinetics of YM178

Netherlands
EMS

Recruiting

Efficacy and Safety of Tanzânia Association in the Treatment of Erectile Dysfunction Associated With Benign Prostatic Hyperplasia

Benign Prostatic Hyperplasia | Erectile Dysfunction

Brazil
Boehringer Ingelheim

Completed

The Impact of Alna® Ocas® on Nocturia in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH)

Prostatic Hyperplasia
The Affiliated Ganzhou Hospital of Nanchang University

Active, not recruiting

Acupuncture Combined With Mirabegron in the Treatment of OAB (ACWMITTOOAB)

Overactive Bladder

China
University Ghent

Withdrawn

Online Contingent Attention Training (OCAT)

Major Depression in Remission

Belgium
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Effect of a Single Dose of Digoxin on the Actions in the Bodies of Healthy Subjects After Having Taken Several Doses of YM178

Healthy

France
Astellas Pharma Inc

Completed

A Study to Evaluate Absorption, Distribution and Elimination of Mirabegron After Oral Administration to Non-elderly Healthy Chinese Subjects

Healthy Subjects | Plasma Concentration of Mirabegron

Japan
Astellas Pharma Inc

Completed

A Study to Assess Pharmacokinetic Interaction of Multiple Dose Ketoconazole on Single Dose YM178 Oral Controlled Absorption System (OCAS) in Healthy Adult Volunteers

Healthy Subjects | Pharmacokinetics of YM178

United States
Thomas Jefferson University
Astellas Pharma Inc

Terminated

Mirabegron in Achalasia: A Clinical and Manometric Proof of Concept Pilot Study

Achalasia

United States
University Ghent
Universidad Complutense de Madrid; Alexianen Zorggroep Tienen

Enrolling by invitation

The Effect of Attention Training on Symptoms and Emotion Regulation in Depressive Patients

Depression

Belgium
Cedars-Sinai Medical Center

Recruiting

Using Mirabegron to Increase BP in Patients With POTS (RAISE BP)

Syncope | Postural Orthostatic Tachycardia Syndrome | Chronic Orthostatic Intolerance

United States
Far Eastern Memorial Hospital

Recruiting

Mirabegron for Female OAB Patients: Comparison of Daytime and Nighttime Dosing

Overactive Bladder Syndrome

Taiwan
University Ghent

Terminated

The Effects of Attention Training on Emotion Regulation and Stress Related Complaints During COVID-19 (OCAT)

Stress | Anxiety | Depressive Symptoms | Rumination

Belgium
Far Eastern Memorial Hospital

Recruiting

Comparisons of the Impact of Monotherapy With Mirabegron or Tolterodine Versus Combined Treatment With Mirabegron and Tolterodine on Autonomic Function and Bladder Blow Flow in Women With Overactive Bladder Syndrome: a Randomized Controlled Study

Female Patients With Overactive Bladder Syndrome

Taiwan
Astellas Pharma Europe Ltd.

Completed

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin) (BESIDE)

Urologic Diseases | Urinary Bladder Diseases | Urinary Bladder Overactive

United States, Armenia, Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, France, Georgia, Germany, Greece, Hungary, Ireland, Israel, Italy, Lebanon, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Slov... and more
Peking Union Medical College Hospital

Not yet recruiting

Mirabegron Combined With Behavioral Intervention for Overactive Bladder：a Prospective Multicenter Randomized Controlled Clinical Study

Overactive Bladder
Astellas Pharma Europe B.V.

Completed

A Study to Compare How Much Solifenacin Succinate and Mirabegron Reach the Blood When Administered Together as Fixed-dose Combination Tablets and With Single Individual Tablets of the Same Medications at Three Dose Levels

Healthy Subjects | Bioavailability | Phase 1

Germany
TransMedics

Terminated

OCS Lung System EXPAND II Trial

Lung Transplantation

United States
Acibadem University

Completed

Carotid Artery Stenting Without Protection

Carotid Arteries

Turkey
Astellas Pharma China, Inc.

Completed

A Study to Investigate the Effect of Food With Mirabegron in Healthy Chinese Participants

Pharmacokinetics of Mirabegron | Food Effect | Healthy Chinese Subjects

China
CHU de Quebec-Universite Laval

Completed

Pilot Study of Mirabegron in Pediatric Patients With Overactive Bladder (Mirabegron)

Overactive Bladder | Urinary Incontinence
Astellas Pharma Inc

Completed

Specified Drug Use-results Survey of Betanis Tablets

Overactive Bladder

Japan
Astellas Pharma Inc

Completed

A Study to Investigate the Food Effect on the Pharmacokinetics of YM178 in Healthy, Non-elderly Volunteers

Healthy Volunteer | Pharmacokinetics of YM178

Japan
Astellas Pharma Inc
Astellas Pharma Taiwan, Inc.

Completed

A Study to Evaluate the Tolerability and Efficacy of Tamsulosin 0.4mg OCAS Formulation in Patients Who Are Unsatisfied With the Treatment of Tamsulosin 0.2mg Conventional Formulation

Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)

Taiwan
University of California, San Francisco

Completed

Trial of Immediate Versus Delayed Initiation of Oral Contraceptive Pills After Abortion

Abortion

United States
University of Pittsburgh

Completed

A Randomized Trial of Carotid Artery Stenting With and Without Cerebral Protection

Carotid Artery Stenosis

United States
Samsung Medical Center

Completed

Prospective Study for Patient Perception of Treatment Satisfaction After Switching to Mirabegron in Patients With Overactive Bladder Who Were Unsatisfied With Efficacy of Antimuscarinic Therapy or Adverse Event.

Overactive Bladder

Korea, Republic of
Treatment Research Institute
National Institute on Drug Abuse (NIDA)

Completed

Development of Coercion Assessment Scale (CAS)

Coercion to Participate in Research

United States
Taipei Veterans General Hospital, Taiwan

Recruiting

Sequencing and Combination of Mirabegron and TTNS in Overactive Bladder Syndrome: a Multicenter, Randomized, Open-label, Crossover Trial

Overactive Bladder Syndrome

Taiwan
Buddhist Tzu Chi General Hospital

Unknown

Therapeutic Efficacy and Safety of Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan

Overactive Bladder Syndrome

Taiwan
Astellas Pharma Europe B.V.

Completed

A Study to Investigate the Effect of Mirabegron (YM178) on Subjects With Mild or Moderate Hepatic Impairment Compared to Healthy Subjects

Healthy Subjects | Pharmacokinetics | Mild and Moderate Hepatic Impairment

Slovakia
Far Eastern Memorial Hospital

Withdrawn

Impact of Beta-3 Agonist on Psychological Distress and Blood Flow of the Bladder in Women With Overactive Bladder Syndrome

Overactive Bladder Syndrome

Taiwan
Seoul National University Hospital

Unknown

MIrabegron With oveRACtive bLadder Symptoms in mEn

Overactive Bladder

Korea, Republic of
Astellas Pharma Inc

Completed

Study of the Effect of Food on the Pharmacokinetics of Mirabegron

Healthy | Pharmacokinetics of Mirabegron

United States
York University
Canadian Institutes of Health Research (CIHR); North York General Hospital

Completed

A Pilot With Interactive Computer-assisted Screening for Mental Health in Primary Care (iCAS)

Mental Health Disorders

Canada
Buddhist Tzu Chi General Hospital

Completed

Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan

Urinary Incontinence | Overactive Bladder Syndrome
Astellas Pharma Inc
Astellas Pharma Taiwan, Inc.

Completed

A Study to Investigate the Safety and Effect of Food on the Pharmacokinetics of YM178 in Healthy Volunteers

Healthy Volunteer | Pharmacokinetics of YM178

Taiwan
Astellas Pharma China, Inc.

Completed

A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder

Urge Incontinence | Overactive Bladder (OAB)

China
Astellas Pharma Inc

Completed

A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment

Renal Impairment

United States
University Hospital, Grenoble

Completed

19/5000 (SYNAPSOT21) Predictive Factors of Sleep Apnea Syndrome in Down Syndrome (SYNAPSOT21)

Sleep Apnea, Obstructive | Down Syndrome | Polysomnography

France
Astellas Pharma Inc

Completed

A Clinical Study to Determine the Effect of YM178 on the Pharmacokinetics of Warfarin in Healthy Subjects

Overactive Bladder | Pharmacokinetics

France
Genuine Research Center, Egypt
Hikma Pharma

Completed

Bioequivalence Study of Solifenacin Succinate & Mirabegron From Mirfenacin MR 5/50 mg Extended Release Tablets (Hikma Pharma, Egypt) Versus Vesicare 5 mg FCT & Betmiga 50 mg Prolonged-Release Tablets (Astellas Pharma Europe B.V, the Netherlands / Astellas Pharma Europe B.V, the Netherlands)

Healthy

Egypt
National Taiwan University Hospital

Completed

Predictors for Retreatement of OAB After DC Mirabegron

Recurrence of Overactive Bladder Syndrome

Taiwan
Astellas Pharma Inc

Completed

Long-Term Specified Drug Use-results Survey of Betanis Tablets

Overactive Bladder

Japan
HealthPartners Institute

Completed

Mirabegron in Parkinson Disease and Impaired Cognition (MICT-PD)

Overactive Bladder | Parkinson Disease | Impaired Cognition

United States
Astellas Pharma Inc

Completed

Pharmacokinetics of Oral Mirabegron With Different Release Rates Versus Intravenous (IV) Mirabegron

Healthy | Pharmacokinetics of Mirabegron

United States
Chang Gung Memorial Hospital

Completed

Comparative Study Between Behavior Therapy and Behavior Therapy Plus Mirabegron in Sexually Active Men With OAB Symptoms

Urinary Bladder, Overactive | Sexual Behavior | Sexual Function Disturbances | Behavior Therapy | Sexual Activity

Taiwan
University of Alabama at Birmingham

Completed

Posterior Tibial Nerve Stimulation (PTNS) Plus Mirabegron to Treat Refractory OAB Symptoms (PTNS-M Study) (PTNS-M)

Overactive Bladder

United States

3

Subscribe